Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio
NCT ID: NCT05170217
Last Updated: 2021-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2017-11-08
2019-06-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be administered, in a randomized order, vaporized cannabis containing one of four different ratios of CBD:THC (0:1, 1:1, 2:1, 3:1). The cannabis administration will follow a standardised inhalation procedure using a medical-grade vaporizer device.
Participants will complete a series of tasks measuring cognition, psychosis, anxiety and other subjective experiences.
The study will be carried out at the NIHR-Wellcome Trust Clinical Research Facility at King's College Hospital.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBD:THC 0:1
Inhalation of cannabis containing only THC
THC
Inhaled cannabis containing 10mg THC
CBD:THC 1:1
Inhalation of cannabis containing THC and CBD
THC
Inhaled cannabis containing 10mg THC
Cannabidiol
Inhaled cannabis containing 10mg CBD
CBD:THC 2:1
Inhalation of cannabis containing THC and CBD
THC
Inhaled cannabis containing 10mg THC
Cannabidiol
Inhaled cannabis containing 20mg CBD
CBD:THC 3:1
Inhalation of cannabis containing THC and CBD
THC
Inhaled cannabis containing 10mg THC
Cannabidiol
Inhaled cannabis containing 30mg CBD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THC
Inhaled cannabis containing 10mg THC
Cannabidiol
Inhaled cannabis containing 10mg CBD
Cannabidiol
Inhaled cannabis containing 20mg CBD
Cannabidiol
Inhaled cannabis containing 30mg CBD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have used cannabis at least once
* Willing to provide written informed consent
* Willing to provide blood samples
* Fluent English speaker
Exclusion Criteria
* Past or present major physical illness
* Past or present substance use disorder
* Past or present use of anti-psychotic or anti-depressant medications
* First degree relative with psychotic disorder
* Currently taking psychotropic medication
* Positive urine drug screen at screening or experimental visits
* Use of alcohol 24h prior to experimental visit or tobacco on the day of experiment
* Pregnancy (current or planned) or lactation in women
* Significant abnormality detected during physical examination at screening visit
* Cannabis use (defined as days in which cannabis is used recreationally) more than once per week on average over the last 12 months
* Any past use of synthetic cannabinoids
* Score of 5 and above on the Fagerstrom Nicotine dependence questionnaire
* BMI classified as obese or underweight
* Taken part in any drug study within the last 30 days or taking part in another study over the course of the trial
* Known drug sensitivity/allergy towards cannabis or Lorazepam
21 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Psychiatry, Psychology and Neuroscience, King's College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oliver D, Englund A, Chesney E, Chester L, Wilson J, Sovi S, Wigroth S, Hodsoll J, Strang J, Murray RM, Freeman TP, Fusar-Poli P, McGuire P. Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study. Addiction. 2024 Feb;119(2):322-333. doi: 10.1111/add.16353. Epub 2023 Oct 11.
Chester LA, Englund A, Chesney E, Oliver D, Wilson J, Sovi S, Dickens AM, Oresic M, Linderman T, Hodsoll J, Minichino A, Strang J, Murray RM, Freeman TP, McGuire P. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study. Cannabis Cannabinoid Res. 2024 Feb;9(1):188-198. doi: 10.1089/can.2022.0174. Epub 2022 Dec 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HR-16/17-4163
Identifier Type: -
Identifier Source: org_study_id